Recurrent numerical aberrations of JAK2 and deregulation of the JAK2-STAT cascade in lymphomas

Modern Pathology

Volumn 22, Issue 3, 2009, Pages 476-487

  Meier, Cecile ^a   Hoeller, Sylvia ^a   Bourgau, Caroline ^a   Hirschmann, Petra ^a   Schwaller, Juerg ^a   Went, Philip ^a   Pileri, Stefano A ^b   Reiter, Andreas ^c   Dirnhofer, Stephan ^a   Tzankov, Alexandar ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

FISH; Gains 9p24; Janus kinase 2; Lymphoma; pSTAT3; pSTAT5

Indexed keywords

JANUS KINASE 2; STAT PROTEIN; STAT5 PROTEIN;

ARTICLE; B CELL LYMPHOMA; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENE MUTATION; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

CHROMOSOME ABERRATIONS; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; JANUS KINASE 2; LYMPHOMA; MUTATION; PROGNOSIS; ROC CURVE; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS;

EID: 61349087903     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2008.207     Document Type: Article

References (40)

1. Ihle JN, Gilliland DG. Jak2: normal function and role in hematopoietic disorders. Curr Opin Genet Dev 2007;17:8-14.
2. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-1061.
3. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-1790.
4. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-397.
5. Adelaide J, Perot C, Gelsi-Boyer V, et al. A t(8;9) translocation with PCM1-JAK2 fusion in a patient with T-cell lymphoma. Leukemia 2006;20:536-537.
6. Bousquet M, Quelen C, De M, et al. The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene. Oncogene 2005;24:7248-7252.
7. Heiss S, Erdel M, Gunsilius E, et al. Myelodysplastic/ myeloproliferative disease with erythropoietic hyperplasia (erythroid preleukemia) and the unique translocation (8;9)(p23;p24): first description of a case. Hum Pathol 2005;36:1148-1151.
8. Mark HF, Sotomayor EA, Nelson M, et al. Chronic idiopathic myelofibrosis (CIMF) resulting from a unique 3;9 translocation disrupting the Janus kinase 2 (JAK2) gene. Exp Mol Pathol 2006;81:217-223.
9. Murati A, Gelsi-Boyer V, Adelaide J, et al. PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid leukemia with t(8;9) translocation. Leukemia 2005;19:1692-1696.
10. Reiter A, Walz C, Watmore A, et al. The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Res 2005;65:2662-2667.
11. Khwaja A. The role of Janus kinases in haemopoiesis and haematological malignancy. Br J Haematol 2006;134:366-384.
12. Joos S, Kupper M, Ohl S, et al. Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells. Cancer Res 2000;60:549-552.
13. Valentino L, Pierre J. JAK/STAT signal transduction: regulators and implication in hematological malignancies. Biochem Pharmacol 2006;71:713-721.
14. Levy DE, Darnell Jr JE. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 2002;3:651-662.
15. Ferrajoli A, Faderl S, Ravandi F, et al. The JAK-STAT pathway: a therapeutic target in hematological malignancies. Curr Cancer Drug Targets 2006;6:671-679.
16. Zamo A, Chiarle R, Piva R, et al. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene 2002;21:1038-1047.
17. Shi X, Franko B, Frantz C, et al. JSI-124 (cucurbitacin I) inhibits Janus kinase-3/signal transducer and activator of transcription-3 signalling, downregulates nucleophosmin-anaplastic lymphoma kinase (ALK), and induces apoptosis in ALK-positive anaplastic large cell lymphoma cells. Br J Haematol 2006;135:26-32.
18. Ding BB, Yu JJ, Yu RY, et al. Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood 2008;111:1515-1523.
19. Melzner I, Weniger MA, Bucur AJ, et al. Biallelic deletion within 16p13.13 including SOCS-1 in Karpas1106P mediastinal B-cell lymphoma line is associated with delayed degradation of JAK2 protein. Int J Cancer 2006;118:1941-1944.
20. Mottok A, Renne C, Willenbrock K, et al. Somatic hypermutation of SOCS1 in lymphocyte-predominant Hodgkin lymphoma is accompanied by high JAK2 expression and activation of STAT6. Blood 2007;110:3387-3390.
21. Weniger MA, Melzner I, Menz CK, et al. Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation. Oncogene 2006;25:2679-2684.
22. Lee JW, Soung YH, Kim SY, et al. JAK2 V617F mutation is uncommon in non-Hodgkin lymphomas. Leuk Lymphoma 2006;47:313-314.
23. Melzner I,Weniger MA, Menz CK, et al. Absence of the JAK2 V617F activating mutation in classical Hodgkin lymphoma and primary mediastinal B-cell lymphoma. Leukemia 2006;20:157-158.
24. Jaffe ES, Harris NL, Stein H, et al. (eds). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, France, 2001.
25. Tzankov A, Meier C, Hirschmann P, et al. Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma. Haematologica 2008;93:193-200.
26. Tzankov A, Gschwendtner A, Augustin F, et al. Diffuse large B-cell lymphoma with over-expression of cyclin E substantiates poor standard treatment response and inferior outcome. Clin Cancer Res 2006;12:2125-2132.
27. Tzankov A, Zimpfer A, Went P, et al. Aberrant expression of cell cycle regulators in Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma. Mod Pathol 2005;18:90-96.
28. Tzankov A,Went P, Zimpfer A, et al. Tissue microarray technology: principles, pitfalls and perspectives-lessons learned from hematological malignancies. Exp Gerontol 2005;40:737-744.
29. Perkins NJ, Schisterman EF, Vexler A. Receiver operating characteristic curve inference from a sample with a limit of detection. Am J Epidemiol 2007;165:325-333.
30. Diehl SA, Schmidlin H, Nagasawa M, et al. STAT3-mediated up-regulation of BLIMP1 Is coordinated with BCL6 down-regulation to control human plasma cell differentiation. J Immunol 2008;180:4805-4815.
31. Scheeren FA, Naspetti M, Diehl S, et al. STAT5 regulates the self-renewal capacity and differentiation of human memory B cells and controls Bcl-6 expression. Nat Immunol 2005;6:303-313.
32. Savage KJ, Monti S, Kutok JL, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2003;102:3871-3879.
33. Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003;198:851-862.
34. Skinnider BF,Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood 2002;99:4283-4297.
35. Holtick U, Vockerodt M, Pinkert D, et al. STAT3 is essential for Hodgkin lymphoma cell proliferation and is a target of tyrphostin AG17 which confers sensitization for apoptosis. Leukemia 2005;19:936-944.
36. Zettl A, Rudiger T, Konrad MA, et al. Genomic profiling of peripheral T-cell lymphoma, unspecified, and anaplastic large T-cell lymphoma delineates novel recurrent chromosomal alterations. Am J Pathol 2004;164:1837-1848.
37. Van Roosbroeck K, Lahortiga I, Cools J, et al. A novel t(4;9)(q21;p24) fuses SEC13A to JAK2 in nodular sclerosis Hodgkin Lymphoma. Haematologica 2007;92(s5):43.
38. Barré B, Vigneron A, Perkins N, et al. The STAT3 oncogene as a predictive marker of drug resistance. Trends Mol Med 2007;13:4-11.
39. Mandell JW. Phosphorylation state-specific antibodies: applications in investigative and diagnostic pathology. Am J Pathol 2003;163:1687-1698.
40. Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004;351:2159-2169.